title: Chronic myeloid leukaemia lymphoid blast crisis. Relevance of molecular analysis at the bcr and immunoglobulin heavy chain gene level in monitoring response to therapy and residual disease.
abstract: Southern blot analyses were performed in sequential DNA samples from 4 patients with Ph' + chronic myeloid leukaemia (CML) who underwent lymphoid or mixed blast crisis (BC). Genomic rearrangements at the breakpoint cluster region (bcr) and immunoglobulin heavy chain (IgH) gene level provided, in these cases, a sensitive and specific evaluation of response to therapy both in terms of blasts and Ph' + cell suppression. Recurrent BC was molecularly characterized in the 4 patients, showing each time identical individual specific DNA rearrangement patterns. Residual blasts were detected in 2 cases during intervening chronic phases by IgH rearrangements. Such findings highlight the specificity of these molecular markers, clearly indicating the failure of ablative therapy in eradicating the neoplastic clone. Finally, molecular and phenotypic identity in individual recurrent BC also suggested, in our cases, a lack of clonal evolution during disease progression.
authors.affiliation: Hematology, Human Biopathology Department, University La Sapienza of Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Lo Coco
authors.forename: D
authors.initials: D
authors.lastname: Diverio
authors.forename: M
authors.initials: M
authors.lastname: Frontani
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Wang
authors.forename: E
authors.initials: E
authors.lastname: Montefusco
authors.forename: P
authors.initials: P
authors.lastname: De Fabritiis
authors.forename: W
authors.initials: W
authors.lastname: Arcese
authors.forename: G
authors.initials: G
authors.lastname: De Rossi
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001752:Blast Crisis / Q000235:genetics*; D015139:Blotting, Southern; D016026:Bone Marrow Transplantation; D004247:DNA / Q000032:analysis; D015321:Gene Rearrangement; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D051562:Proto-Oncogene Proteins c-bcr
chemical_list: D000970:Antineoplastic Agents; D007143:Immunoglobulin Heavy Chains; D011518:Proto-Oncogene Proteins; D004247:DNA; D011505:Protein-Tyrosine Kinases; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr